Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$9.32 USD
-0.67 (-6.71%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $9.28 -0.04 (-0.43%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Foghorn Therapeutics Inc. [FHTX]
Reports for Purchase
Showing records 1 - 20 ( 83 total )
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology- ESMO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 Update in 4Q24, Looks to Energize the Potential of Targeting BAF; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q2 Financials; Topline AML Data Ahead for FHD-286 in Q4
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Where the Brook Is Deep; State of Acute Myeloid Leukemia Treatment
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Near/Long-Term Value Driven by FHD-286 in AML (2H24) And Diverse Pipeline Optionality
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Why Investors Should Take Note of the Renaissance Happening in Chromatin Biology
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Showcases Robust Pipeline, Capabilities; Shares Appear Attractive
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
AACR?24 Event Highlights Formidable Novel Oncology Agents; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Cutting Through the Fog of Drug Development With Multiple Attacks on BAF: Reit Buy and $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; CBP/EP300 Data at AACR, FHD-286 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; CBP/EP300 Data at AACR, FHD-286 Data in 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Lily?s Selection of Foghorn?s FHD-909 Reinforces the Druggability of the Chromatin Remodeling System (CRS); Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A